MCID: PRL014
MIFTS: 31

Paralytic Squint

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Paralytic Squint

MalaCards integrated aliases for Paralytic Squint:

Name: Paralytic Squint 12 15
Paralytic Strabismus 12 73
Incomitant Dissociation 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10863
ICD10 33 H49 H49.9
ICD9CM 35 378.5 378.50
UMLS 73 C0152221

Summaries for Paralytic Squint

MalaCards based summary : Paralytic Squint, also known as paralytic strabismus, is related to kearns-sayre syndrome and strabismus. An important gene associated with Paralytic Squint is TUBB3 (Tubulin Beta 3 Class III), and among its related pathways/superpathways is Glypican 1 network. The drugs Acetylcholine and abobotulinumtoxinA have been mentioned in the context of this disorder. Affiliated tissues include eye.

Wikipedia : 76 Strabismus, also known as crossed eyes, is a condition in which the eyes do not properly align with each... more...

Related Diseases for Paralytic Squint

Diseases related to Paralytic Squint via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 kearns-sayre syndrome 31.3 KIF21A PHOX2A TUBB3
2 strabismus 31.0 CHN1 KIF21A PHOX2A TUBB3
3 oculomotor nerve paralysis 30.7 CHN1 KANTR
4 tukel syndrome 30.6 CHN1 KIF21A PHOX2A TUBB2B TUBB3
5 fourth cranial nerve palsy 29.1 CHN1 HCK PRL PRNP RANBP2
6 tubulinopathy-associated dysgyria 10.9 TUBB2B TUBB3
7 fibrosis of extraocular muscles, congenital, 2 10.8 KIF21A PHOX2A
8 marcus gunn phenomenon 10.7 CHN1 TUBB3
9 ovarian carcinosarcoma 10.7 FUT2 TUBB3
10 congenital ptosis 10.7 CHN1 KIF21A TUBB3
11 deafness, autosomal dominant 28 10.7 CHN1 KIF21A TUBB3
12 neonatal anemia 10.7 TUBB2B TUBB3
13 abducens nerve disease 10.6
14 ptosis 10.5 KIF21A PHOX2A TUBB3
15 alternating esotropia 10.5 CHN1 KANTR
16 exotropia 10.4 CHN1 KIF21A PHOX2A TUBB3
17 ocular motility disease 10.4 CHN1 KIF21A PHOX2A TUBB3
18 facial paralysis 10.4 CADM1 TUBB3
19 third cranial nerve disease 10.4 CHN1 KANTR
20 duane retraction syndrome 10.4 CHN1 EPHA4 KIF21A TUBB3
21 pylorospasm 10.3 HCK KANTR
22 hyperhidrosis, gustatory 10.3 HCK KANTR
23 tolosa-hunt syndrome 10.2
24 anismus 10.2 FUT2 KANTR
25 cerebellopontine angle meningioma 10.2 KANTR SAMHD1
26 auditory agnosia 10.2 KANTR PRNP
27 anteroseptal myocardial infarction 10.1 FUT2 KANTR
28 tabes dorsalis 10.1 KANTR SH3BP5
29 peripheral nervous system disease 10.1 CHN1 KANTR KIF21A TUBB3
30 fourth cranial nerve palsy, familial congenital 10.1
31 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 1 10.1
32 gaze palsy, familial horizontal, with progressive scoliosis, 1 10.1
33 total third-nerve palsy 10.1
34 chronic progressive external ophthalmoplegia 10.1
35 trochlear nerve disease 10.1
36 autosomal dominant progressive external ophthalmoplegia 10.1
37 maternally-inherited progressive external ophthalmoplegia 10.1
38 congenital trochlear nerve palsy 10.1
39 accommodative esotropia 10.0 CHN1 KANTR SAMHD1
40 dengue virus 10.0
41 dengue disease 10.0
42 exposure keratitis 10.0 KANTR TUBB3
43 central nervous system disease 10.0 KANTR PRNP TUBB3
44 mitral valve stenosis 10.0 HCK SAMHD1
45 nervous system disease 9.9 KANTR PRNP TUBB3
46 keratopathy 9.9
47 thrombosis 9.9
48 lyme disease 9.9
49 blepharospasm 9.9
50 cranial nerve disease 9.8 CHN1 KANTR KIF21A PHOX2A TUBB3

Graphical network of the top 20 diseases related to Paralytic Squint:



Diseases related to Paralytic Squint

Symptoms & Phenotypes for Paralytic Squint

Drugs & Therapeutics for Paralytic Squint

Drugs for Paralytic Squint (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 3 51-84-3 187
2 abobotulinumtoxinA Phase 3
3 Botulinum Toxins Phase 3
4 Botulinum Toxins, Type A Phase 3
5 Cholinergic Agents Phase 3
6 Neuromuscular Agents Phase 3
7 Neurotransmitter Agents Phase 3
8 onabotulinumtoxinA Phase 3
9 Peripheral Nervous System Agents Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus Completed NCT01584843 Phase 3 GSK1358820

Search NIH Clinical Center for Paralytic Squint

Genetic Tests for Paralytic Squint

Anatomical Context for Paralytic Squint

MalaCards organs/tissues related to Paralytic Squint:

41
Eye

Publications for Paralytic Squint

Articles related to Paralytic Squint:

(show all 18)
# Title Authors Year
1
Paralytic strabismus and papilloedema caused by dural sinus thrombosis after bee sting. ( 25234425 )
2014
2
Acquired paralytic strabismus in Southern Taiwan. ( 23608076 )
2013
3
Paralytic strabismus in South African Black and mixed race children--a 15-year clinic-based review. ( 23171209 )
2012
4
Paralytic squint due to abducens nerve palsy: a rare consequence of dengue fever. ( 22799448 )
2012
5
Paralytic strabismus: third, fourth, and sixth nerve palsy. ( 20638001 )
2010
6
Five cases of paralytic strabismus as a rare feature of lyme disease. ( 19193112 )
2009
7
General principles in the surgical treatment of paralytic strabismus. ( 21149177 )
2008
8
Filamentary keratopathy caused by corneal occlusion by large-angle paralytic strabismus. ( 17133065 )
2006
9
Botulinum toxin in the treatment of paralytic strabismus and essential blepharospasm. ( 8125543 )
1993
10
Paralytic squint treated with acupuncture. ( 6570146 )
1984
11
The use of prisms in paralytic squint. ( 900621 )
1977
12
A surgery on twenty six thousand and three hundred seventy eight patients with convergent squint (26378), thirteen thousand, one hundred and eighty one patients with divergent squint (13181), one thousand and twenty nine patients of vertical squint (1029), ten thousand and one hundred thirty nine patients of heterophoria (10139) and two thousand sixty one patients of paralytic squint (2061) seen during the past ten years at Giza Ophthalmic Hospital Squint Clinic from the year 1960 to the year 1970. ( 4666806 )
1972
13
Diagnosis of paralytic squint. ( 5154750 )
1971
14
NON-PARALYTIC squint. ( 13450382 )
1957
15
Clinical orthoptic procedure: paralytic squint. ( 20295365 )
1947
16
Paralytic squint. ( 20295367 )
1947
17
SOME CASES OF PARALYTIC SQUINT. ( 18169478 )
1937
18
Surgical Treatment of Non-Paralytic Squint. ( 29013305 )
1937

Variations for Paralytic Squint

Expression for Paralytic Squint

Search GEO for disease gene expression data for Paralytic Squint.

Pathways for Paralytic Squint

Pathways related to Paralytic Squint according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.04 HCK PRNP

GO Terms for Paralytic Squint

Cellular components related to Paralytic Squint according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.44 CHN1 EPHA4 GABBR1 HCK IRF6 KIF21A

Biological processes related to Paralytic Squint according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of axonogenesis GO:0050770 9.16 CHN1 EPHA4
2 motor neuron axon guidance GO:0008045 8.96 CHN1 EPHA4
3 negative regulation of long-term synaptic potentiation GO:1900272 8.62 EPHA4 PRNP

Sources for Paralytic Squint

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....